And if Jason's LymPro revenue estimates are proven to be unrealistic, as I believe they will be, the need for cash to support ongoing clinical trials will be less of a concern. Some are worrying about this now. I tend not to worry about things that haven't happened yet, and may not happen at all if the company's plan proves to be sound.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links